menu
    • menu

    Company profile for KaliVir Immunotherapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from The University of Pittsburgh’s world-class onco...
    KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from The University of Pittsburgh’s world-class oncolytic virus and immunotherapy research program.KaliVir is engineering vaccinia virus-based oncolytic viral immunotherapies that can be delivered intravenously to cancer patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    KaliVir ImmunotherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    240 Alpha Drive Pittsburgh, PA 15238
    Telephone
    Telephone
    1.412.435.6730
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://kalivir.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    KaliVir & Roche Partner To Test VET3-TGI With Atezolizumab
    KaliVir & Roche Partner To Test VET3-TGI With Atezolizumab

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251119270996/en/KaliVir-Immunotherapeutics-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Roche-to-Evaluate-VET3-TGI-in-Combination-with-Atezolizumab-Tecentriq-in-Advanced-Solid-Tumors

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    KaliVir Completes 1st IV Cohort in STEALTH-001 Solid Tumor Study
    KaliVir Completes 1st IV Cohort in STEALTH-001 Solid Tumor Study

    01 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251001426597/en/KaliVir-Immunotherapeutics-Announces-Completion-of-First-Intravenous-Patient-Cohort-of-STEALTH-001-Study-Evaluating-VET3-TGI-in-Patients-with-Advanced-Solid-Tumors

    BUSINESSWIRE
    01 Oct 2025
    Share Share
    KaliVir Completes First Cohort in STEALTH-001 Cancer Trial
    KaliVir Completes First Cohort in STEALTH-001 Cancer Trial

    20 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250520615879/en/KaliVir-Immunotherapeutics-Announces-Completion-of-First-Cohort-of-STEALTH-001-Study-Evaluating-VET3-TGI-in-Patients-with-Advanced-Solid-Tumors

    BUSINESSWIRE
    20 May 2025
    Share Share
    KaliVir Immunotherapeutics Details Presentation at 2025 AACR Meet
    KaliVir Immunotherapeutics Details Presentation at 2025 AACR Meet

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325264319/en/KaliVir-Immunotherapeutics-Announces-Details-of-Presentation-at-2025-American-Association-for-Cancer-Research-AACR-Annual-Meeting

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    KaliVir Immunotherapeutics Strengthens Portfolio with 3 New Patents
    KaliVir Immunotherapeutics Strengthens Portfolio with 3 New Patents

    18 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241118517681/en

    BUSINESSWIRE
    18 Nov 2024
    Share Share
    Matica Biotechnology Establishes CDMO Partnership with KaliVir
    Matica Biotechnology Establishes CDMO Partnership with KaliVir

    24 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241024631162/en

    BUSINESSWIRE
    24 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search